Mabylon AG
Alcide Barberis is the CEO at Mabylon AG, a board member at Banca Raiffeisen Tre Valli società cooperativa, EffRx Pharmaceuticals SA, and Oncalis AG. Alcide also serves as the Incubator Director at USI Startup Centre, Faculty at BioBusiness Course_USI Università della Svizzera italiana, and as the Executive Director at AGIRE Foundation. With a background in Molecular Biology, Alcide holds a PhD from the University of Zurich and has worked as a Research Associate at Harvard University.
This person is not in any teams
This person is not in any offices
Mabylon AG
Mabylon AG, a private Swiss biotech company, is leading innovation in antibody-based treatments for severe allergies, inflammation, and neurological disorders. Our B-cell screening platform identifies natural human antibodies with high specificity and therapeutic potential. MY006, our first-in-class multispecific antibody therapeutic for peanut allergy, is tackling the growing food allergy market.